Core Insights - SenesTech has entered a distribution agreement with Bradley Caldwell, Inc. to enhance the availability of Evolve™ Rodent Birth Control in rural America [1][2] - The partnership aims to leverage BCI's extensive network of over 8,000 dealers to improve access to rodent control solutions in agricultural communities [1][2] - This agreement represents a significant step in SenesTech's commercialization strategy, with BCI's initial order being the largest distributor stocking order received by the company [3] Company Overview - SenesTech specializes in fertility control for managing animal pest populations, with products like ContraPest and Evolve designed to be humane and effective [4] - The company focuses on providing sustainable pest management solutions that integrate into existing pest management programs [4] Strategic Benefits - The partnership with BCI is expected to accelerate market penetration in underserved areas where traditional rodenticides face challenges [7] - BCI customers will gain a competitive edge by offering a scientifically-backed, humane alternative to traditional poisons [7] - The collaboration supports SenesTech's long-term growth strategy, anticipating revenue increases from expanded retail sales and new customer acquisition [7]

Core Insights - SenesTech, Inc. reported a 17% increase in revenues for Q1 2025, reaching $485,000 compared to $415,000 in Q1 2024, with Evolve product sales growing 40% year-over-year, now accounting for 79% of total revenue [8][3] - The company achieved a record gross profit margin of 64.5%, up from 32.5% in the same quarter last year [8] - The net loss for Q1 2025 was $1.7 million, slightly improved from a loss of $1.8 million in Q1 2024, while adjusted EBITDA loss improved to $1.5 million from $1.7 million [8] Operational and Strategic Highlights - The Evolve™ Rat and Evolve™ Mouse products are now the largest revenue drivers for SenesTech, reflecting a successful product expansion strategy [3] - E-commerce revenue more than doubled year-over-year, with a 107% increase attributed to improved platform functionality and digital marketing efforts [4] - The company has expanded Evolve deployments in major U.S. municipalities, with positive early adoption in Chicago and a pilot program in New York City [5] International Growth - SenesTech has signed distribution agreements in eleven countries and territories, with product shipments already initiated in The Netherlands, Hong Kong, the UAE, and the Maldives [6] - Regulatory approvals are pending in Australia and New Zealand, with additional launches planned for later in 2025 [6] Financial Performance - The company reported a gross profit of $313,000 for Q1 2025, compared to $135,000 in Q1 2024, indicating improved operational efficiency [17] - Total current assets increased to $3.164 million as of March 31, 2025, up from $2.813 million at the end of 2024 [16] - The company has lowered its breakeven revenue threshold from $12 million to approximately $7 million, indicating a path toward positive cash flow [6]